
Samantha L. Shterengarts
Examiner (ID: 2, Phone: (571)270-5316 , Office: P/1626 )
| Most Active Art Unit | 1626 |
| Art Unit(s) | 4131, 1623, 1626 |
| Total Applications | 2313 |
| Issued Applications | 1786 |
| Pending Applications | 96 |
| Abandoned Applications | 469 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15768781
[patent_doc_number] => 20200115408
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-16
[patent_title] => TREHALOSE ANALOGUES
[patent_app_type] => utility
[patent_app_number] => 16/714017
[patent_app_country] => US
[patent_app_date] => 2019-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20260
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16714017
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/714017 | Trehalose analogues | Dec 12, 2019 | Issued |
Array
(
[id] => 16635222
[patent_doc_number] => 10913717
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-02-09
[patent_title] => Solid state forms of N-[2-[(I S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-L H-isoindol-4-yl]acetamide and process for preparation thereof
[patent_app_type] => utility
[patent_app_number] => 16/706695
[patent_app_country] => US
[patent_app_date] => 2019-12-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 10
[patent_no_of_words] => 9971
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16706695
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/706695 | Solid state forms of N-[2-[(I S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methyl sulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-L H-isoindol-4-yl]acetamide and process for preparation thereof | Dec 6, 2019 | Issued |
Array
(
[id] => 16735546
[patent_doc_number] => 10961181
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-30
[patent_title] => Cationic lipids for therapeutic agent delivery formulations
[patent_app_type] => utility
[patent_app_number] => 16/700304
[patent_app_country] => US
[patent_app_date] => 2019-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 20236
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700304
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/700304 | Cationic lipids for therapeutic agent delivery formulations | Dec 1, 2019 | Issued |
Array
(
[id] => 16735546
[patent_doc_number] => 10961181
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-30
[patent_title] => Cationic lipids for therapeutic agent delivery formulations
[patent_app_type] => utility
[patent_app_number] => 16/700304
[patent_app_country] => US
[patent_app_date] => 2019-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 20236
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700304
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/700304 | Cationic lipids for therapeutic agent delivery formulations | Dec 1, 2019 | Issued |
Array
(
[id] => 16735546
[patent_doc_number] => 10961181
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-30
[patent_title] => Cationic lipids for therapeutic agent delivery formulations
[patent_app_type] => utility
[patent_app_number] => 16/700304
[patent_app_country] => US
[patent_app_date] => 2019-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 20236
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700304
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/700304 | Cationic lipids for therapeutic agent delivery formulations | Dec 1, 2019 | Issued |
Array
(
[id] => 16421876
[patent_doc_number] => 20200347074
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-11-05
[patent_title] => COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/700200
[patent_app_country] => US
[patent_app_date] => 2019-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 39864
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 182
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700200
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/700200 | Compounds that participate in cooperative binding and uses thereof | Dec 1, 2019 | Issued |
Array
(
[id] => 16735546
[patent_doc_number] => 10961181
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-30
[patent_title] => Cationic lipids for therapeutic agent delivery formulations
[patent_app_type] => utility
[patent_app_number] => 16/700304
[patent_app_country] => US
[patent_app_date] => 2019-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 7
[patent_no_of_words] => 20236
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 107
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16700304
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/700304 | Cationic lipids for therapeutic agent delivery formulations | Dec 1, 2019 | Issued |
Array
(
[id] => 17343556
[patent_doc_number] => 20220009887
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-13
[patent_title] => CYANOARYL-ANILINE COMPOUNDS FOR TREATMENT OF DERMAL DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/294808
[patent_app_country] => US
[patent_app_date] => 2019-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32239
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -52
[patent_words_short_claim] => 191
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17294808
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/294808 | Cyanoaryl-aniline compounds for treatment of dermal disorders | Nov 19, 2019 | Issued |
Array
(
[id] => 18384469
[patent_doc_number] => 11655238
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-05-23
[patent_title] => MMPL3 inhibitors, compositions and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/295227
[patent_app_country] => US
[patent_app_date] => 2019-11-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25421
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 223
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17295227
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/295227 | MMPL3 inhibitors, compositions and uses thereof | Nov 19, 2019 | Issued |
Array
(
[id] => 16090347
[patent_doc_number] => 20200199160
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => STAT3 DIMERIZATION INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/685461
[patent_app_country] => US
[patent_app_date] => 2019-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29244
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16685461
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/685461 | STAT3 dimerization inhibitors | Nov 14, 2019 | Issued |
Array
(
[id] => 17134752
[patent_doc_number] => 11136298
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-10-05
[patent_title] => Method for producing fullerene derivative
[patent_app_type] => utility
[patent_app_number] => 16/680570
[patent_app_country] => US
[patent_app_date] => 2019-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7276
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16680570
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/680570 | Method for producing fullerene derivative | Nov 11, 2019 | Issued |
Array
(
[id] => 17363519
[patent_doc_number] => 11230534
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-01-25
[patent_title] => KDM1A inhibitors for the treatment of disease
[patent_app_type] => utility
[patent_app_number] => 16/672083
[patent_app_country] => US
[patent_app_date] => 2019-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 65099
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 213
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16672083
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/672083 | KDM1A inhibitors for the treatment of disease | Oct 31, 2019 | Issued |
Array
(
[id] => 16236714
[patent_doc_number] => 20200253948
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-13
[patent_title] => CANNABINOID RECEPTOR AGONISTS AND SERINE HYDROLASE ENZYME INHIBITOR BASED ANXIOLYTIC THERAPEUTIC PRODUCT
[patent_app_type] => utility
[patent_app_number] => 16/670679
[patent_app_country] => US
[patent_app_date] => 2019-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19364
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670679
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/670679 | CANNABINOID RECEPTOR AGONISTS AND SERINE HYDROLASE ENZYME INHIBITOR BASED ANXIOLYTIC THERAPEUTIC PRODUCT | Oct 30, 2019 | Abandoned |
Array
(
[id] => 18127910
[patent_doc_number] => 11554105
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-17
[patent_title] => Combinations of artemisinins, BCL-2 inhibitors, and kinase inhibitors for cancer treatment
[patent_app_type] => utility
[patent_app_number] => 16/670218
[patent_app_country] => US
[patent_app_date] => 2019-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 38
[patent_no_of_words] => 21213
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 62
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670218
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/670218 | Combinations of artemisinins, BCL-2 inhibitors, and kinase inhibitors for cancer treatment | Oct 30, 2019 | Issued |
Array
(
[id] => 15828471
[patent_doc_number] => 20200129517
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-30
[patent_title] => COMBINATION THERAPY FOR TREATMENT OF HEMATOLOGICAL DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/670289
[patent_app_country] => US
[patent_app_date] => 2019-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8539
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 120
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670289
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/670289 | Combination therapy for treatment of hematological diseases | Oct 30, 2019 | Issued |
Array
(
[id] => 17335978
[patent_doc_number] => 20220002309
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => SSAO INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/287781
[patent_app_country] => US
[patent_app_date] => 2019-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43343
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -62
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287781
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/287781 | SSAO INHIBITORS AND USES THEREOF | Oct 22, 2019 | Abandoned |
Array
(
[id] => 17200018
[patent_doc_number] => 20210340113
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => PROCESS FOR PREPARATION OF OPTICALLY ENRICHED ALDOL COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 17/284199
[patent_app_country] => US
[patent_app_date] => 2019-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9471
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 285
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284199
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/284199 | PROCESS FOR PREPARATION OF OPTICALLY ENRICHED ALDOL COMPOUNDS | Oct 17, 2019 | Abandoned |
Array
(
[id] => 17214435
[patent_doc_number] => 20210347772
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => AZAINDOLE INHIBITORS OF WILD-TYPE AND MUTANT FORMS OF LRRK2
[patent_app_type] => utility
[patent_app_number] => 17/283441
[patent_app_country] => US
[patent_app_date] => 2019-10-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22067
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283441
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/283441 | Azaindole inhibitors of wild-type and mutant forms of LRRK2 | Oct 15, 2019 | Issued |
Array
(
[id] => 16841664
[patent_doc_number] => 11013723
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-05-25
[patent_title] => Solid forms of a thiazolidinone compound, compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/653173
[patent_app_country] => US
[patent_app_date] => 2019-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 21971
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 358
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16653173
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/653173 | Solid forms of a thiazolidinone compound, compositions and methods of use thereof | Oct 14, 2019 | Issued |
Array
(
[id] => 16842824
[patent_doc_number] => 11014897
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-05-25
[patent_title] => Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/653643
[patent_app_country] => US
[patent_app_date] => 2019-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 37
[patent_figures_cnt] => 38
[patent_no_of_words] => 26709
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16653643
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/653643 | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof | Oct 14, 2019 | Issued |